Methylation Sciences Inc (MSI), based in Canada, is a company focused on developing pharmaceuticals based on molecules which are proven to be clinically effective but which have yet to be exploited in major pharmaceutical markets.
SAMe
MSI is actively developing proprietary formulations of naturally-occurring S-Adenosyl Methionine (SAMe) as a stand-alone pharmaceutical product and/or in combination (adjunctive) with current therapies for the treatment of major depressive disorder.
Efficacy and safety profile
A long record of clinical use and large body of credible, supporting research indicates that SAMe is safe, well tolerated and clinically effective. Our proprietary formulations of SAMe exhibit a broad range of benefits, including extended release, improved PK profile and reduced dosing requirements to achieve a therapeutic response.
www.methylationsciences.com
Location: United Kingdom, England
Member count: 51-200
Total raised: $48.369921M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Inventages | inventages... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 06.10.2016 | - | $30M | - | finsmes.co... |
| 29.09.2011 | Series A | $18.369921... | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 08.10.2016 | Quark Vent... | Quark Venture Inc., a venture ... | - | - | citybizlis... |
| 06.10.2016 | Methylatio... | Methylation Sciences Inc., a V... | Canada | - | finsmes.co... |
| 29.09.2011 | MSI Methyl... | MSI Methylation Sciences, Inc.... | Canada fu... | - | finsmes.co... |